New Case Study: Discovery of GALNT3 Inhibitors Using a Universal Glycosyltransferase Assay and Orthogonal Pooled Screening
Friday, 27 November 2015
Glycosyltransferase (GT) enzymes participate in diverse metabolic and regulatory roles by catalyzing the transfer of sugars to protein, lipid and carbohydrate acceptors as well as to other molecules. Within the GT family, there are over 20 distinct polypeptide N-acetylgalactosaminyltransferases (GALNTs) that catalyze the initial step of O-glycosylation. GALNT3 overexpression and dysregulation has been directly linked
No Comments
Join us in Boston for DOT 2015
Wednesday, 02 September 2015
Visit booth 29 and ask how our latest developments can accelerate your research. Join us from September 21st through 24th at the 13th Annual Discovery on Target conference in Boston, Massachusetts. Visit booth 29 and ask about the latest developments in Transcreener® HTS Assays and how to integrate these assays into your
- Published in News
“Simplifying HTS with Orthogonal Pooled Screening” Webinar – Encore Presentation
Monday, 17 August 2015
Access to this webinar is now available anytime to suit your schedule! In this webinar, Dr. Mel Reichman, Director of Chemical Genomics Center at the Lankenau Institute for Medical Research (LIMR, Wynnewood, PA) describes the Orthogonal Pooled Screening (OPS™) Platform that he developed to provide a drastically more efficient and less expensive approach for rapidly finding
- Published in News
Jump-Starting Residence Time Assays
Monday, 10 August 2015
New Case Study: Determination of Inhibitor Residence Times for a Phosphodiesterase using the Transcreener® AMP2/GMP2 FP Assay Analysis of inhibitor residence times is increasingly being incorporated into lead development efforts because longer engagement with the target can result in improved efficacy, increased therapeutic window and reduced side effects. BellBrook Labs scientist, Meera Kumar, recently used
- Published in News
Tuning Kinase Drug Residence Times for Reversible Covalent Inhibitors
Thursday, 25 June 2015
Drug residence time, the length of time that an inhibitor remains bound to its target, is increasingly being recognized as a key parameter impacting pharmacodynamic activity. Longer residence times translate into higher efficacy and fewer side effects because a lower circulating dose of drug is required to maintain an effective level of target engagement. One
- Published in News
New Publication: Optimizing Histone Methyltransferase Assays
Tuesday, 09 June 2015
See our latest publication, “Biochemical Assay Development for Histone Methyltransferases Using a Transcreener-Based Assay for S-Adenosylhomocysteine” in Assay and Drug Development Technologies Screening or profiling histone methyltransferases (HMTs) can often require challenging assay development. Their complex enzyme and substrate requirements compound the difficulties imposed by their unusual (read SLOW) kinetic properties. In a recent study
- Published in News
View Our Kinase Inhibitor Residence Time Webinar Anytime!
Monday, 11 May 2015
Analysis of inhibitor residence times is increasingly being incorporated into lead development efforts because longer engagement with the target can result in improved efficacy, increased therapeutic window and reduced side effects. Though residence time can be determined using immobilized ligand methods such surface plasmon resonance, conjugation of drugs can affect their binding. In this webinar,
- Published in HTS Assays, News
NEW! Orthogonal Pooled Screening – 5X Higher Efficiency, 80% Fewer Resources
Wednesday, 15 April 2015
Do what you’re good at with 5-fold greater efficiency—and leave the rest to us. We are pleased to announce that BellBrook Labs is partnering with the Lankenau Institute for Medical Research (LIMR) to provide access to an innovative Orthogonal Pooled Screening (OPS™) Platform. The OPS™ Platform provides drug discovery researchers with a drastically more efficient
- Published in News
Join our webinar—HTS glycoslytransferase assays
Tuesday, 17 February 2015
Next up in our BellBrook Labs Webinar Series: Register Now! Transcreener® HTS Assays for UDP, GDP, and CMP as a Universal Glycosyltransferase Assay Platform BellBrook’s Transcreener® HTS assays enable robust screening and profiling of glycosyltransferases using mix-and-read assays for immunodetection of UDP, GDP, and CMP nucleotide products using FP, FI, or TR-FRET readouts. On February
- Published in News
Join us in Washington DC for SLAS 2015!
Wednesday, 28 January 2015
Come see what we’ve been up to and learn how our latest developments can help accelerate your research. Join us at the 4th Annual Conference of the Society for Laboratory Automation and Screening February 7th – 11th in Washington DC. Visit us to learn about the latest developments in Transcreener® HTS Assays including our new
- Published in News
